Our preclinical study demonstrates that sitravatinib is a potent FLT3 TKI and can overcome clinically-relevant gilteritinib resistance mediated by F691L mutation or increased FL/FGF2, which may represent a promising second-line TKI for AML patients harboring FLT3 mutations. Here, FLT3 is linked to acute myeloid leukemia.